Extrait

Background and study aims Screening for prostate cancer continues to cause controversy because of concerns about over-diagnosis and unnecessary treatment. The aim of this study is to help policy makers decide whether PSA testing for prostate cancer should be introduced by evaluating the effectiveness of PSA testing in reducing prostate cancer mortality (i.e. the number of deaths), and its cost-effectiveness (i.e. comparing the health-related costs in combination with the effectiveness of PSA testing, in order to assist policy makers in their decisions about how to achieve the best use of resources). Who can participate? Men aged 50 - 69 years from about 573 GP practices in eight UK centres (Sheffield, Newcastle, Bristol, Birmingham, Cardiff, Leeds, Cambridge and Leicester). What does the study involve? Participants will be randomly allocated to one of two groups. One group is invited to have a PSA test (‘population-based PSA testing’) and the other group continues to receive standard NHS care in the UK, based on the NHS prostate cancer risk management programme. The study involves medical records being looked at by trained researchers working with local NHS Trusts. Trained researchers will put information about any tests or treatment received for prostate problems onto a computer, making sure no personal details (name, address etc.) will be recorded. Data will be identified only by a study number. What are the possible benefits and risks of participating? The study will have no impact on an individual’s medical care. There are no direct benefits, although participation will contribute towards a better understanding of how prostate problems are currently diagnosed and managed by UK doctors. Where is the study run from? University of Bristol (UK) When is the study starting and how long is it expected to run for? March 2004 to March 2016 Who is funding the study? Cancer Research UK (CRUK) (UK) Who is the main contact? Prof Richard Martin

Critère d'inclusion

• Prostate cancer

Liens

• isrctn
• ictrp